Close Menu

NEW YORK – Mission Bio said today that it has raised $70 million in a Series C funding round.

The South San Francisco-based firm said it will use the funding to scale its Tapestri singe-cell multi-omics technology, to expand the company's reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

Mission Bio's Tapestri platform can simultaneously detect DNA and protein changes from the same cell, which it believes is necessary for developing impactful precision therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.